1 week Ago By ABMN Staff
Barclays PLC lowered its position in Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND – Free Report ) by 8.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 39,972 shares of the biotechnology company’s stock after selling 3,484 shares during the period.
Barclays PLC’s holdings in Ligand Pharmaceuticals were worth $4,282,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also made changes to their positions in the business. Smartleaf Asset Management LLC raised its position in Ligand Pharmaceuticals by 119.
5% during the fourth quarter. Smartleaf Asset Management LLC now owns 406 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 221 shares during the last quarter. Redwood Park Advisors LLC purchased a new position in shares of Ligand Pharmaceuticals during the 4th quarter worth approximately $48,000.
Sterling Capital Management LLC raised its position in shares of Ligand Pharmaceuticals by 825.4% during the 4th quarter. Sterling Capital Management LLC now owns 546 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 487 shares during the last quarter.
US Bancorp DE lifted its stake in Ligand Pharmaceuticals by 14.8% in the 4th quarter. US Bancorp DE now owns 758 shares of the biotechnology company’s stock valued at $81,000 after buying an additional 98 shares in the last quarter.
Finally, KBC Group NV grew its holdings in Ligand Pharmaceuticals by 49.7% during the 4th quarter. KBC Group NV now owns 904 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 300 shares during the last quarter.
91.28% of the stock is currently owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth A number of equities analysts have recently weighed in on the company.
Stifel Nicolaus started coverage on Ligand Pharmaceuticals in a report on Thursday, April 10th. They issued a “buy” rating and a $143.00 price target for the company.
StockNews.com raised shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 15th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock.
Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $146.43. Ligand Pharmaceuticals Price Performance LGND opened at $108.
07 on Monday. Ligand Pharmaceuticals Incorporated has a 12 month low of $69.51 and a 12 month high of $129.
90. The business has a 50-day moving average of $108.78 and a two-hundred day moving average of $112.
39. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of 43.
06 and a beta of 1.07. Insider Buying and Selling In other Ligand Pharmaceuticals news, CFO Octavio Espinoza sold 5,000 shares of the stock in a transaction that occurred on Tuesday, March 4th.
The shares were sold at an average price of $115.03, for a total transaction of $575,150.00.
Following the transaction, the chief financial officer now owns 18,879 shares of the company’s stock, valued at $2,171,651.37. This trade represents a 20.
94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink . Corporate insiders own 5.
90% of the company’s stock. Ligand Pharmaceuticals Company Profile ( Free Report ) Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
See Also Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND – Free Report ). Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
